8 weeks
8 weeks. However, other promising providers, such as gevokizumab, IL-1 obstructing monoclonal antibody, tadekinig alfa, a human being recombinant IL-18-binding protein, and tranilast, an analog of a tryptophan metabolite, are currently being tested. Anakinra, canakinumab and rilonacept caused impressive improvements in both systemic and musculoskeletal symptoms. Furthermore, the anti-IL-1 therapy allowed corticosteroid tapering and, in […]